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Background-—In cardiomyocytes from patients with hypertrophic cardiomyopathy, mechanical dysfunction and arrhythmogenicity
are caused by mutation-driven changes in myofilament function combined with excitation-contraction (E-C) coupling abnormalities
related to adverse remodeling. Whether myofilament or E-C coupling alterations are more relevant in disease development is
unknown. Here, we aim to investigate whether the relative roles of myofilament dysfunction and E-C coupling remodeling in
determining the hypertrophic cardiomyopathy phenotype are mutation specific.
Methods and Results-—Two hypertrophic cardiomyopathy mouse models carrying the R92Q and the E163R TNNT2 mutations were
investigated. Echocardiography showed left ventricular hypertrophy, enhanced contractility, and diastolic dysfunction in both
models; however, these phenotypes were more pronounced in the R92Q mice. Both E163R and R92Q trabeculae showed
prolonged twitch relaxation and increased occurrence of premature beats. In E163R ventricular myofibrils or skinned trabeculae,
relaxation following Ca2+ removal was prolonged; resting tension and resting ATPase were higher; and isometric ATPase at maximal
Ca2+ activation, the energy cost of tension generation, and myofilament Ca2+ sensitivity were increased compared with that in wild-
type mice. No sarcomeric changes were observed in R92Q versus wild-type mice, except for a large increase in myofilament Ca2+
sensitivity. In R92Q myocardium, we found a blunted response to inotropic interventions, slower decay of Ca2+ transients, reduced
SERCA function, and increased Ca2+/calmodulin kinase II activity. Contrarily, secondary alterations of E-C coupling and signaling
were minimal in E163R myocardium.
Conclusions-—In E163R models, mutation-driven myofilament abnormalities directly cause myocardial dysfunction. In R92Q,
diastolic dysfunction and arrhythmogenicity are mediated by profound cardiomyocyte signaling and E-C coupling changes. Similar
hypertrophic cardiomyopathy phenotypes can be generated through different pathways, implying different strategies for a
precision medicine approach to treatment. ( J Am Heart Assoc. 2017;6:e005407. DOI: 10.1161/JAHA.116.005407.)
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H ypertrophic cardiomyopathy (HCM) is the most commonMendelian cardiac disease,1 defined as a disease of the
sarcomere because of its association with myofilament gene
mutations in most patients.2 HCM is a progressive disease with
different clinical stages3 and a large spectrum of clinical
phenotypes,4,5 ranging from asymptomatic individuals with
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minimal echocardiographic anomalies6 to patients with
extreme left ventricular (LV) remodeling and advanced heart
failure.3 Despite the vast archipelago of clinical manifestations,
LV hypertrophy (LVH), diastolic dysfunction, and an arrhythmic
propensity are considered hallmarks of the disease and occur in
most patients7,8 independently of their genetic profile.
Biophysical experiments have demonstrated how HCM-
related mutations primarily alter sarcomere function, ie,
crossbridge cycling kinetics9,10 or the switched-off state of
the thin filament,11 leading to increased energy consumption
during tension generation or diastole.12–14 In addition to altered
sarcomere energetics, increased myofilament Ca2+ sensitivity
has often been reported in human HCM myocardium,9,15 both
as a direct effect of the sarcomeric proteinmutation15,16 and as
a consequence of secondary myofilament posttranslational
modifications.17 The complex and poorly known secondary
remodeling process that occurs in HCM involves a number of
myofilament, sarcoplasmic reticulum (SR), and sarcolemmal
alterations,18–20 reflecting adaptive/maladaptive modifica-
tions in various signaling pathways.21,22 We recently demon-
strated that in myocardial samples from patients with severe
HCM who underwent septal myectomy, changes of calcium/
calmodulin-dependent protein kinase II (CaMKII)–dependent
signaling lead to prolonged action potentials, cellular arrhyth-
mias, prolonged Ca2+ transients, and increased diastolic
intracellular [Ca2+] and [Na+].22 Such abnormalities appeared
unrelated to patients’ individual mutations.22 However, the
scarce availability of human samples does not allow us to
properly define whether HCM-related secondary remodeling is
truly independent of the underlying genotype.
In an era of emerging therapies that use a precision
medicine molecular approach, this notion may be directly
relevant to future management of the disease. To investigate
this complex issue, we used 2 HCM mouse models reflecting
the human phenotype but caused by different cardiac
troponin T (TnT) mutations. We assessed how primary
changes in myofilament function concur with secondary
abnormalities of cardiomyocyte excitation-contraction (E-C)
coupling to determine contractile impairment and arrhythmo-
genicity in HCM.
Methods
Detailed methods are available in Data S1.
TnT Mutant Transgenic Mouse Lines
All experimental protocols were performed in agreement with
current Italian and European regulations and were approved
by the local institutional review board and the animal-welfare
committee of the Italian Ministry of Health. We used a total of
sixty-seven 6- to 8-month-old male C57BL/6N transgenic
mice carrying the R92Q13,23 or E163R24 mutation in the
TNNT2 gene, as well as wild-type (WT) littermates: 22 R92Q,
24 E163R, and 21 WT mice were used for the experiments
described below. The mouse colonies were housed in the
animal facility of the University of Florence and all experi-
ments were conducted locally. The 2 transgenic lines were
generated in laboratories as previously described.23,24
Myocardial Mechanics From the Whole Heart to
the Single Myofibril
Echocardiography was performed on isoflurane-anesthetized
mice as previously described25 to characterize LV morphology
Clinical Perspective
What is New?
• Two hypertrophic cardiomyopathy (HCM) mouse models
with R92Q and E163R TNNT2 mutations were characterized
with echocardiographic and biophysical studies to assess
the relative roles of myofilament dysfunction and excitation-
contraction coupling remodeling in HCM pathophysiology.
• Both models exhibited diastolic dysfunction and increased
arrhythmogenicity.
• The E163R model showed severe myofilament abnormalities
including altered sarcomere energetics, with preserved
intracellular Ca2+ transients.
• The R92Q model presented profound excitation-contraction
coupling alterations that slowed down Ca2+ transients and
twitch contractions in the absence of myofilament energetic
changes.
• Increased calcium/calmodulin-dependent protein kinase II
activity and increased myofilament Ca2+ sensitivity were
detected in both mutants, but the changes were much larger
in the R92Q model.
What are the Clinical Implications?
• The notion that cellular remodeling is mutation specific in
HCM may be relevant for treatment and may explain why
some patients with HCM may not respond to specific
therapies.
• Drugs targeting ion channels or Ca2+ fluxes, such as late Na-
current blockers or diltiazem, may be more effective in the
presence of significant cardiomyocyte excitation-contrac-
tion coupling remodeling (eg, R92Q mutation).
• When HCM mutations have a direct impact on sarcomere
energetics (eg, E163R), sarcomere-targeting drugs may be
preferred; trials of novel myosin inhibitors in patients are
currently underway.
• Disease mechanisms that are common to different HCM
mutations (calcium/calmodulin-dependent protein kinase II,
myofilament Ca2+ sensitivity) should be considered as valid
targets for future therapies.
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and systolic and diastolic function using B-mode imaging and
Doppler measurements of transmitral blood flow. LV intact
trabeculae were dissected from explanted hearts26,27 and
used to record isometric force during electrical stimulation
with different pacing protocols at baseline and following b-
adrenergic activation.18 Skinned trabeculae were used to
obtain pCa-tension curves as previously described.28 Sarcom-
ere energetics was assessed in skinned trabeculae by
simultaneous measurement of isometric force and ATPase
activity with an enzyme-coupled assay.12,14 Single myofibrils
were isolated from mouse ventricular samples and used for
mechanical measurements using a fast solution switching
technique to assess maximal Ca2+-activated tension, resting
tension, and the kinetics of active tension generation and
relaxation.9,29 Myofibril suspensions were also used to
measure resting ATPase by assessing phosphate production
with a rapid colorimetric method.
Assessment of Morphofunctional Myocardial and
Cellular Remodeling
Single cardiomyocytes were isolated from excised hearts via
enzymatic dissociation and used for intracellular Ca2+mea-
surements using Ca-sensitive fluorescent dyes18,27 to evalu-
ate the amplitude and kinetics of Ca2+ transients, diastolic
[Ca2+], and the rate of spontaneous Ca2+ release, during
stimulation with field electrodes.30 To assess T-tubule density,
myocytes were stained with membrane-selective dyes and
observed with a confocal microscope.18,30 Fast-frozen LV
myocardial samples were processed to obtain total proteins,
which were used for Western blot studies to assess expres-
sion and phosphorylation of CaMKII,22 phospholamban,
troponin I, and nuclear factor of activated T cell, as well as
the expression of SERCA. Formalin-fixed LV slices were
stained with Picrosirius red and used to assess intramyocar-
dial fibrosis.30
Statistical Analysis
Data from myofibrils, cells, and muscles are expressed as
meanSEM (number of samples and animals are indicated in
the respective figure legends). Statistical analysis was per-
formed as previously described,22,30 using SPSS version 23.0
(IBM) and STATA version 12.0 (StataCorp). In brief, all sets of
variables were checked for normality (Shapiro-Wilk test) and
for homogeneity of variances among groups (Levene’s test).
The statistical tests used to calculate P values for each data
set are indicated in the respective figure legends. For variables
where a single measurement for each mouse is included (eg,
echocardiography, Western blot), the 3 different groups were
compared using 1-way ANOVA with Tukey correction (for
normally distributed homoscedastic data sets), Kruskal-Wallis
test with Dunn’s multiple comparison test (for non-Gaussian
data sets), or Welch’s ANOVA with Games-Howell test (for
heteroscedastic groups). For variables where measurements
from an unequal number of different samples (eg, cells or
trabeculae) from each mouse were included (eg, ion fluores-
cence and myofibrils isometric force data), we used linear
mixed models to compare data groups, using the xtmixed
function of the STATA 12.0 program (StataCorp). To account
for intra-subject correlation, we included mouse-id as a
random-effect term in the model. The Tukey-Kramer post
hoc correction method was used to compute P values for all
pairwise comparisons, using the pwcompare with mcompare
(tukey) option in STATA. Overall, P<0.05 was considered
statistically significant. The range of calculated P values for
each comparison (0.05>P>0.01, 0.01>P>0.001, or P<0.001)
is indicated in the respective figure panels using symbols: red
symbols refer to R92Q versus WT comparisons, blue symbols
to E163R versus WT comparisons, and purple symbols to
R92Q versus E163R comparisons.
Results
Hallmarks of Human HCM Phenotype are Present
in Both R92Q and E163R Mouse Hearts
Echocardiographic measurements were performed in anes-
thetized male mice from the 3 study groups (WT, R92Q, and
E163R), using a standardized protocol.31 Average heart rate
during echocardiographic measurement was similar in the 3
groups: 58542 beats per minute in WT, 57938 beats per
minute in E163R, and 57345 beats per minute in R92Q
mice. Representative images of parasternal long-axis views of
the left ventricle are reported in Figure 1A. In both R92Q and
E163R mice, septal thickness was significantly increased
compared with WT mice (Figure 1B), highlighting the presence
of asymmetric LVH in both HCM models. Short-axis views at
different levels of the left ventricle were used to estimate LV
volumes (Figure 1C). In R92Q compared with WT and E163R
mice, we found a modest reduction of end-diastolic and end-
systolic LV volumes. This is consistent with more severe LVH
in R92Q mice, as the increase of wall thickness diminishes LV
cavity volume.
In both R92Q and E163R mice compared with WT mice, we
observed increased ejection fraction and septal fractional
thickening during contraction (Figure 1D). In E163R mice,
stroke volume and cardiac output were increased compared
with that in WT mice (Figure 1E). In R92Q mice, instead, no
differences were noted compared with that in WT mice,
indicating that enhanced LV ejection fraction compensates for
the reduced LV volumes.
Doppler studies of transmitral blood flow velocity (Fig-
ure 1F) were performed in 4-chamber views to assess LV
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diastolic function. Reduced transmitral blood flow velocity
during early diastole (ie, reduced E-wave amplitude), paral-
leled by an increased proportion of LV diastolic filling during
atrial contraction (ie, increased A-wave amplitude), is widely
recognized as an index of diastolic dysfunction. In both
mutants, and more severely in R92Q, early LV filling was
reduced and E/A ratio decreased (Figure 1G). Furthermore,
in both R92Q and E163R compared with WT mice, we found
prolonged isovolumic LV relaxation time, an additional index
of diastolic dysfunction (Figure 1G). Taken together, these
echocardiographic measurements indicate that 3 hallmarks
of human HCM phenotype, ie, LVH, LV hypercontractility,
and diastolic dysfunction are reproduced in both HCM
models.
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Figure 1. Echocardiographic measurements. A, Representative parasternal long-axis views of the left ventricle at end diastole from wild-type
(WT), R92Q, and E163R mice. The horizontal scale bars equal 1 mm. B, Thickness of the interventricular septum (IVS) measured at end diastole
(left) and at end systole (right) in WT, R92Q, and E163R mice. C, Left ventricular (LV) volumes are calculated using the Simpson technique at end
diastole (left) and end systole (right) in mice from the 3 study groups. D, Systolic thickening of the IVS (left) and LV ejection fraction (LV-EF%,
right), are expressed as percentage of the diastolic values, measured in mice from the 3 cohorts. E, Stroke volume (SV) calculated from Simpson
volumes and cardiac output (CO). F, Representative transmitral blood flow velocity curves recorded using pulsed-wave Doppler
echocardiography in apical views from WT, R92Q, and E163R mice. The vertical scale bar equals 100 mm/s. Early (passive, E) and late
(atrial contraction, A) LV filling waves are indicated on the traces. G, Ratio between E and A waves (E/A ratio, left) and isovolumic LV relaxation
time (IVRT, right) in mice from the 3 study cohorts. (B, E) Statistical tests: 1-way ANOVA with Tukey correction. G, Statistical test: Welch’s
ANOVA with Games-Howell test. (B through E and G) MeansSE from 10 mice per group. *=0.05>P>0.01; **=0.01>P>0.001.
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Twitch Relaxation is Prolonged and Spontaneous
Activity Increased in Both R92Q and E163R
Trabeculae
Isometric force was measured from intact left and right
ventricular trabeculae or thin papillary muscles during field
stimulation at 1 Hz, 30°C, and 2 mmol/L extracellular [Ca2+]
(Figure 2). The amplitude of twitch contraction was similar in
WT, R92Q, and E163R mice (Figure 2A and 2B). The baseline
diastolic tension tended to be higher in E163R and R92Q
compared with WT mice, although the difference was not
significant (Figure 2B). Both E163R and R92Q trabeculae
showed prolonged twitch duration compared with WT, caused
by a significant prolongation of relaxation times (Figure 2A
and 2C). This result is in line with the prolonged isovolumic LV
relaxation time observed in vivo. The prolonged relaxation
cannot be explained by changes in the myosin heavy chain
isoform as myosin heavy chain-a is the only significantly
expressed isoform (>99%) in all 3 mouse lines.
We then analyzed the occurrence of spontaneous contrac-
tions in R92Q, E163R, and WT trabeculae to estimate the
arrhythmogenic propensity associated with each mutation. In
all mouse lines, the rate of spontaneous contractions was
extremely low at baseline conditions (at 1-Hz stimulation, <1%
of preparations showed spontaneous contractions). A specific
protocol to increase the probability of spontaneous events
(Figure 2D) was applied, featuring the combination of isopro-
terenol 107 mol/L and a burst of high-rate (3 Hz) stimuli
followed by a 30-second simulation pause. With this protocol,
spontaneous activity occurred in more than 40% of E163R and
R92Q trabeculae, while arrhythmic beats arose in only 10% of
WT trabeculae (Figure 2E).
Responses to b-Adrenergic Stimulation and
Changes in Stimulus Interval Suggest Impaired
SR Function in R92Q but not E163R Myocardium
Next, we studied the response of muscle contraction to
steady-state stimulation at different frequencies (0.2–6 Hz) at
baseline (Figure 3) and in the presence of isoproterenol
(107 mol/L) (Figure S1). While twitch amplitude at 1 Hz was
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Figure 2. Steady-state isometric twitches and occurrence of spontaneous contractions during stimulation
pauses in intact trabeculae. A, Representative twitches elicited at 1 Hz in left ventricular trabeculae of wild-
type (WT), R92Q, and E163R mice. B, Passive and active twitch tension measured during 1-Hz stimulation.
C, Time from stimulus to peak contraction (TTP) and time from peak to 50% and 90% relaxation (R50% and
R90%, respectively), measured in twitches at 1 Hz. D, Representative traces of the occurrence of
spontaneous activity following a stimulation pause after 3-Hz stimulation burst in the presence of
isoproterenol 107 mol/L in intact trabeculae from the 3 study groups. At variance with WT, R92Q and
E163R muscles display frequent spontaneous beats during pauses. The grey lines indicate electrical stimuli.
E, Percentage of trabeculae that show spontaneous contractions following the protocol described in D. (B,
C, E) MeansSE from 9 WT (6 mice), 11 R92Q (8 mice), and 9 E163R (6 mice) trabeculae. Statistical tests:
linear mixed models with Tukey-Kramer correction (corrected for heteroschedasticity in E). *=0.05>P>0.01;
**=0.01>P>0.001.
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the same in all experimental groups, the rate-dependent
increase of contractile force observed in WT and E163R
trabeculae at frequencies above 2 Hz was significantly
blunted in the R92Q trabeculae (Figure 3A and 2B). The
increase of contractile force in response to isoproterenol was
also significantly reduced in R92Q versus WT and E163R
trabeculae (Figure S1). Mechanisms responsible of potentiat-
ing contraction in response to a high pacing rate or b-
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Figure 3. Steady-state and short-term interval force relationships. A, Representative
superimposed force traces from trabeculae of wild-type (WT), R92Q, and E163R mice,
stimulated at 0.2 Hz, 2 Hz, and 5 Hz. B, Relationship between active twitch force and
stimulation frequency (0.1–6 Hz) in trabeculae from the 3 groups of mice. §=0.05>P>0.01
(R92Q vsWT) for frequencies 0.1 to 0.5 Hz and 4 Hz and 0.01>P>0.001 for 5 to 6 Hz. C,
Time from peak to 50% relaxation (R50%, right), measured in steady-state twitches at
different stimulation frequencies. ##=0.01>P>0.001 at all frequencies. D, Representative
force traces of post-rest potentiation in trabeculae from WT, R92Q, and E163R mice;
steady-state stimulation 3 Hz, pause duration 10 seconds. E, Average percentage increase
of twitch force after different pause intervals from a basal frequency of 3 Hz in the 3 study
groups. ‡=0.05>P>0.01 at resting intervals of 20 to 60 seconds. F, Ca2+ recirculation
fraction estimated by the decline of potentiated beats following a period of high stimulation
rate in trabeculae from WT, R92Q, and E163R mice at baseline and in the presence of
isoproterenol 107 mol/L (Iso). G, Mechanical restitution protocol: representative traces
from WT, R92Q, and E163R trabeculae: steady-state stimulation 1 Hz, premature interval
250 ms. H, Restitution curves show the fractional recovery of force (percent of 1 Hz
steady-state peak force) in response to the premature stimulus plotted against the
premature interval. Each curve was fitted by a single exponential to obtain the time
constant of mechanical restitution (s): mean s values are reported in the inset. (B, C through
F, H) MeanSE from 9 WT (6 mice), 11 R92Q (8 mice), and 9 E193R (6 mice) trabeculae,
Statistical tests: linear mixed models with Tukey-Kramer correction (corrected for
heteroschedasticity in C and F). *=0.05>P>0.01; **=0.01>P>0.001.
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adrenergic stimulation mainly rely on SR function.32 The
results suggest that SR function is impaired in R92Q but not
E163R trabeculae. Relaxation times were prolonged in the 2
mutants at all investigated pacing rates, but rate adaptation of
twitch duration (ie, acceleration of contraction kinetics with
increase in stimulation frequency) was preserved in both
R92Q and E163R models (Figure 3A through 3C). The positive
lusitropic effect of b-adrenergic stimulation was also pre-
served in both mutants (Figure S1).
Stimulation pauses of variable duration were inserted into
a steady-state 1-Hz series (Figure 3D) and the relative
increase in amplitude of the first twitch after the pause was
estimated (post-rest potentiation) and plotted against the rest
interval (Figure 3F). Maximum post-rest potentiation was
markedly lower in R92Q compared with WT and E163R
trabeculae and was reached at shorter rest intervals. Pauses
enhance twitch force mainly by allowing more Ca2+ to fill the
SR during the prolonged diastolic period, thus favoring a
larger Ca2+ release after the pause.33 Therefore, diminished
post-rest potentiation of R92Q myocardium suggests
impaired SR Ca2+ reuptake.
The decay of post-rest potentiation was studied to
estimate SR Ca2+ recirculating fraction, a parameter that is
generally assumed to reflect the relative contributions of
SERCA and sarcolemma to cytosolic Ca2+ removal.34 In R92Q
compared with WT or E163R trabeculae, SR Ca2+ recirculating
fraction was significantly reduced both at baseline and in the
presence of isoproterenol (Figure 3F), suggesting impaired
SERCA function in the R92Q model.
Last, in intact trabeculae of the 3 mouse lines, we analyzed
mechanical restitution by introducing a premature stimulus
into a regular stimulus sequence at 1 Hz. The premature
“extrasystolic” contraction was reduced in amplitude com-
pared with steady-state twitches (Figure 3G). The amplitude
of the extrasystolic beat was plotted against the premature
stimulus interval to obtain mechanical restitution curves
(Figure 3F). In both R92Q and E163R versus WT trabeculae,
the rate of mechanical restitution was faster (Figure 3F
through G), suggestive of a shorter refractoriness of SR Ca2+
release27 and/or a lower Ca2+ threshold for myofilament
activation.35
Ca2+ Handling, CaMKII Signaling, and Fibrosis in
R92Q, WT, and E163R Myocardium
To further investigate the E-C coupling process, intracellular
Ca2+ measurements were performed in isolated, Fluoforte-
loaded cardiomyocytes during electrical field stimulation at
35°C. Representative traces are reported in Figure 4A and
show considerable differences between the 2 mutants. At all
stimulation frequencies tested, intracellular Ca2+ transient
decay was markedly prolonged and its peak amplitude
decreased in R92Q cardiomyocytes compared with both WT
and E163R cardiomyocytes. Notably, WT and E163R
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cardiomyocytes exhibited the same Ca2+ transient amplitude
and kinetics (Figure 4A through 4C). Diastolic [Ca2+]i was
increased in both mutants but the largest change occurred in
the R92Q model (Figure 4D).
To detect potential structural changes of T-tubules, which
may affect E-C coupling,18 we labelled intact cardiomyocytes
with a membrane-selective dye and imaged them with a
confocal myocroscope. T-tubule profile was quantified with
dedicated software36 based on fast Fourier transform. The
loss of T-tubules, which was modest but statistically signif-
icant, was more pronounced in R92Q cardiomyocytes com-
pared with E163R cardiomyocytes (Figure S2).
Next, we studied the occurrence of spontaneous Ca2+
waves and spontaneous Ca2+ transients after applying a
specific stimulation protocol, ie, a burst of high-rate stimuli
followed by a stimulation pause (Figure 4E). The occurrence
of spontaneous Ca2+ waves and spontaneous Ca2+ transients
was significantly higher in R92Q and E163R versus WT models
at baseline, and the difference increased after the adminis-
tration of isoproterenol (107 mol/L).
To identify some of the potential mechanisms underlying the
observed Ca2+ handling differences, fast-frozen LV myocardial
samples fromWT, R92Q, and E163R animals were processed to
obtain total proteins, which were used for Western blot studies
aimed at identifying changes in CaMKII signaling and other
molecular markers of cardiac remodelling, as previously
described in human myocardium (Figure 5A).22,37 Notably,
CaMKII autophosphorylation, a marker of CaMKII activation,
was increased in hearts from both R92Q and E163R compared
with WT mice. Interestingly, the increase of CaMKII autophos-
phorylation was significantly more pronounced in R92Q com-
pared with E163R hearts (Figure 5B). The total amount of
SERCA protein was reduced in both R92Q and E163R hearts
(Figure S3). Contrarily, phospholamban expression was signif-
icantly increased only in R92Q mice. Interestingly, the ratio
between SERCA and phospholamban expression levels was
markedly decreased in R92Q hearts. In E163R hearts, SERCA/
phospholamban ratio was also reduced compared with WT, but
was 3 times higher than that in R92Q. Finally, phospholamban
phosphorylation at the protein kinase A site was decreased in
both mutant lines, but the decrease was larger in R92Q hearts
(Figure S3). The observed changes of the expression and
phosphorylation of Ca2+-handling proteins are in line with the
marked reduction of the kinetics of Ca2+ transient decay
observed in R92Q cardiomyocytes.
Intramyocardial fibrosis is a pathological hallmark of HCM,
both in human and in mouse models.30 We therefore explored
disease-related remodeling of extracellular matrix in the 2
transgenic lines by using Picrosirius red staining on LV tissue
sections (Figure 5C). The amount of intramyocardial fibrosis,
as identified by the extent of Picrosirius red–positive area in
stained tissue sections, was increased in both R92Q and
E163R hearts. However, the increase was more pronounced in
R92Q versus E163R myocardium (Figure 5D).
We conclude that Ca2+ handling alterations in R92Q mice
(driven, at least in part, by altered CaMKII signaling) may
account for prolonged relaxation in trabeculae and diastolic
dysfunction observed in vivo. In E163R mice, the extent of
secondary myocardial remodeling, although qualitatively sim-
ilar to that of R92Q mice, is much more limited. Indeed, the
phenotype of E163R hearts is determined by different patho-
mechanisms.
Sarcomere Mechanical and Kinetic Properties are
Altered in E163R but Preserved in R92Q
Myofibrils
Ventricular myofibrils from R92Q, E163R, and WT hearts,
mounted for force recording at 15°C and optimum myofila-
ment overlap, were maximally calcium-activated (pCa 4.5) and
fully relaxed (pCa 8.0) by fast solution switching, as previously
described.9 Figure 6A through 6C shows representative
traces of activation-relaxation protocols, while average data
for the 3 myofibril groups are reported in Figure 6D through
6F. R92Q myofibrils showed no changes compared with WT.
Specifically, maximal isometric tension, resting tension, the
rates of tension generation and tension redevelopment, and
all kinetic parameters of tension relaxation were the same in
R92Q and WT myofibrils (Figure 6). E163R myofibrils, instead,
showed a number of significant changes compared with both
WT and R92Q. While maximal isometric tension was pre-
served (Figure 6A), resting tension was significantly increased
and tension activation and tension redevelopment were
faster, indicative of faster crossbridge turnover in the E163R
sarcomeres (Figure 6B, 6D, and 6E). Significant changes were
also found in the kinetics of tension relaxation of E163R
myofibrils (Figure 6C and 6F). As previously described,34,35
the time course of tension relaxation upon Ca2+ removal in all
myofibril groups was biphasic with an early slow relaxation
phase, which occurs while sarcomeres are isometric, followed
by a fast exponential phase, starting with the “give” of few
sarcomeres and dominated by intersarcomere dynamics. The
rate of the early phase (slow kREL), predominantly reflecting
the apparent rate with which attached crossbridges leave
force-generating states,34,35 was significantly faster in the
E163R myofibrils, indicating that this mutation may increase
the energy cost of active tension generation10 (Figure 6F). In
spite of the acceleration in kinetics of the slow isometric
relaxation phase, the overall duration of the force relaxation
transient was prolonged in E163R myofibrils compared with
both WT and R92Q myofibrils. Indeed, the duration of the slow
tension decay was significantly longer while the rate of the
fast exponential phase (fast kREL) was significantly slower in
E163R myofibrils (Figure 6F).
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Figure 4. Intracellular Ca2+ measurements in intact ventricular cardiomyocytes. A, Representative
superimposed Ca2+ transients elicited at 1 Hz in wild-type (WT) and R92Q cardiomyocytes (left) and WT and
E163R cells (right). B, Time from stimulus to peak (Peak Time), time from peak to 50% and 90% decay of
Ca2+ transients (D50% and D90%, respectively) elicited at 1 Hz in cardiomyocytes from WT, R92Q, and
E163R mouse hearts. C, Amplitude of Ca2+ transients in cardiomyocytes from the 3 study groups at
different stimulation frequencies. D, Diastolic Ca2+ levels expressed as arbitrary units of fluorescence
intensity during steady-state stimulation at different frequencies in cells from mice of the 3 cohorts. (B
through D) MeanSE from 79 WT (6 mice), 91 R92Q (7 mice), and 109 E163R (8 mice) cardiomyocytes.
*P<0.05. (E) Representative traces showing the stimulation pause protocol used to elicit spontaneous Ca2+
events in WT, R92Q, and E163R cardiomyocytes at basal conditions and in the presence of isoproterenol
107 mol/L (Iso). Notably, R92Q and E163R cardiomyocytes showed frequent Ca2+ waves (denoted by gray
arrows) and premature Ca2+ transients (black arrows). The black lines below the traces indicate the times of
stimulation. F, Frequency of spontaneous Ca2+ waves and spontaneous Ca2+ transients during stimulation
pauses in WT, R92Q, and E163R cardiomyocytes at basal conditions and in the presence of Iso. MeanSE
from 88 WT (5 mice), 102 R92Q-KET (7 mice), and 131 R92Q-RAN (7 mice) cardiomyocytes. (B, D, F)
Statistical tests: linear mixed models with Tukey-Kramer correction (correction for heteroschedasticity was
applied in F). *=0.05>P>0.01; **=0.01>P>0.001; ***=P<0.001.
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Prolonged tension relaxation and increased diastolic
tension suggest that diastolic dysfunction of E163R hearts
is primarily related to sarcomere dysfunction. Mutation-driven
impairment of the blocked state of thin filaments, by allowing
recruitment of force-generating crossbridges in the absence
of Ca2+, may be responsible for both the relaxation and
diastolic tension changes found in the E163R myofibrils. This
mechanism can also lead to increased sarcomere energy
consumption at rest.
Energetic Changes are Only Observed in E163R
Skinned Trabeculae, While Myofilament Ca2+
Sensitivity is Enhanced in Both Mutants
Direct demonstration of the specific impact of E163R on
sarcomere energetics at rest and during contraction was
obtained by simultaneously measuring isometric tension and
ATPase activity in demembranated ventricular trabeculae at
20°C. Representative recordings are reported in Figure 7A.
Maximal Ca2+-activated tension was the same in all groups of
preparations (Figure 7B), in line with what observed in
myofibrils. Resting tension tended to be higher in E163R
trabeculae compared with WT and R92Q, although, at variance
with myofibrils, this difference did not reach statistical
significance (Figure 7B). Importantly, in E163R skinned tra-
beculae, both resting and maximal Ca2+-activated ATPase were
increased compared with WT and R92Q (Figure 7C). An
increase in resting ATPase was confirmed in E163R trabeculae
by measuring steady-state ATP hydrolysis from myofibril
suspensions in relaxing solution (Figure S4). The ratio between
maximal Ca2+-activated ATPase activity and active tension,
representing the energetic cost of tension generation, was
A
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Figure 5. Molecular investigation of calcium/calmodulin-dependent protein
kinase II (CaMKII) signaling and myocardial fibrosis. A, Representative Western
blots for total CaMKII, phospho-CaMKII at tyrosine 287, and GAPDH. B, Average
values in wild-type (WT), R92Q, and E163R hearts (7 samples for each groups). The
intensity of individual bands was quantified and normalized to that of GAPDH.
Relative intensities of WT were set at 1. Statistical test: 1-way ANOVA with Tukey
correction. *=0.05>P>0.01. C, Representative histological sections of mouse left
ventricular myocardium from WT, R92Q, and E163R mice. The left and central
images show sections stained with hematoxylin (purple, marking cell nuclei) and
Picrosirius red (pink) at different magnification; the bright pink strands denote
collagen fibers. Sections shown on the right are stained with hematoxylin and eosin.
D, Fraction of the myocardium occupied by collagen fibers, expressed as
percentage of the whole section’s area, measured in samples from mice of the 3
groups. MeanSE from 9 mice per group. Five histological sections of the same
size from each mouse were analyzed to calculate the extent of Picrosirius red–
positive areas. Statistics: Kruskal–Wallis test with Dunn’s multiple comparisons
test. *=0.05>P>0.01; **=0.01>P>0.001.
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markedly higher in E163R compared with both WT and R92Q
trabeculae (Figure 7D). The result was confirmed by measuring
tension cost from the slope of the ATPase/tension plot
obtained in skinned trabeculae by simultaneously measuring
isometric ATPase and tension at different levels of Ca2+
activation (Figure S5).
Mean pCa-active tension curves obtained from skinned
trabeculae showed that myofilament Ca2+ sensitivity was
significantly increased in both R92Q and E163R compared
with WT preparations (Figure 7E). The change was milder in
the E163R trabeculae and much more marked in the R92Q
preparations that showed the highest pCa50 value.
Discussion
In HCM, functional alterations at the sarcomere level9,14 are
associatedwith secondarymodifications in E-C coupling that are
responsible for theproarrhythmogenic phenotypeand contribute
to alterations of cardiac mechanical function.22 The relative
contribution of primary, mutation-driven, sarcomeric changes
versus adverse cardiomyocyte remodeling to the development of
HCM phenotype is unclear, and, in the present work, we suggest
that it varies depending on the underlying mutation. Previous
work on human samples17,22 described a number of “disease-
specific” aspects of HCM-related myocardial remodeling, differ-
ent from those observed in heart failure or secondary hypertro-
phy and without a major impact of the specific patient genotype.
Here, we characterized in vivo heart phenotype and in vitro
biophysical changes in sarcomere function and E-C coupling in 2
HCM mouse models carrying different mutations in cardiac TnT
and found that HCM pathophysiology is “mutation specific”
rather than “disease specific” (Figure 8).
Similar Phenotypes Through Different Pathogenic
Pathways
Findings from echocardiographic and Doppler measurements
showed that several hallmarks of human HCM phenotype
C
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Figure 5. Continued.
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(increased septal thickness, increased ejection fraction,
diastolic dysfunction) are present in both HCM mouse models,
with the phenotype more pronounced in the R92Q mice
(Figure 1). Mechanical experiments in intact trabeculae
demonstrated that (in the absence of a switch in myosin
isoforms) isometric twitch relaxation was markedly prolonged
and resting tension tended to increase in both HCM mice
compared with WT mice (Figure 2A through C), in line with the
diastolic dysfunction observed in vivo (Figure 1F and 1G).
Compared with WT, both HCM models exhibited a significantly
higher frequency of spontaneous activity during pauses,
following a period of high-frequency stimulation in the
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Figure 6. Mechanical measurements on single myofibrils. A, Tension generation and relaxation: representative tension responses of wild-type
(WT), E163R, and R92Q myofibrils, maximally activated (pCa 4.5) and fully relaxed (pCa 8) by fast solution switching technique at 15°C, [MgATP]
5 mmol/L; [Pi] <5 lmol/L. The timing of solution switch is indicated by black arrows. (B through C) Superimposed representative tension
curves from single myofibrils isolated from WT, R92Q, and E163R hearts, highlighting the kinetics of force generation (B) and relaxation (C). Of
note, relaxation is biphasic, with an initial linear phase (slow) followed by an exponential decay of force (fast phase). D, Resting tension in WT,
R92Q, and E163R myofibrils. E, Kinetic parameters of tension generation in WT, R92Q, and E163R myofibrils: time constant of tension activation
(kACT, left) and of tension redevelopment upon myofibril relengthening after forced slacking (kTR, right). F, Kinetic parameters of myofibril
relaxation: duration of the slow linear phase (Dslow, left) and time constant of the slow phase of relaxation (Slow kREL, center) and of the fast
exponential phase (Fast kREL, right). (D through F) MeanSE from 32 WT, 34 R92Q, and 36 E163R myofibrils, 3 mice per group. Statistical tests:
linear mixed models with Tukey-Kramer correction. *=0.05>P>0.01; **=0.01>P>0.001.
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Figure 7. Isometric tension and ATPase measurements in skinned ventricular trabeculae. A, Representative
tension (top) and ATPase activity (bottom) traces from wild-type (WT), R92Q, and E163R trabeculae that were
maximally Ca2+-activated (pCa 4.5) at 20°C. (B through D) MeanSE of maximal active tension (P0) and resting
tension (B), maximal Ca2+-activated ATPase and resting ATPase activities (C), tension cost estimated as the
ratio between maximal Ca2+-activated ATPase and maximal active tension (D) in WT (n=16), R92Q (n=12), and
E163R (n=15) trabeculae. (E) Tension-pCa curves (left) and mean values of pCa at half-maximal activation
(pCa50, right) from WT (n=10), R92Q (n=7), and E163R (n=9) trabeculae. Statistical tests: linear mixed models
with Tukey-Kramer correction. *=0.05>P>0.01; **=0.01>P>0.001.
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presence of isoproterenol (Figure 2D and 2E). Previous
telemetry evaluations in the R92Q models highlighted
increased occurrence of both atrial and ventricular arrhyth-
mias,38 while no evaluation of the arrhythmic burden was
performed on living E163R mice.
In spite of the similarities between the 2 mouse models,
further experiments investigating the inotropic reserve of
intact trabeculae indicated that the function of the Ca2+-
handling machinery was substantially different (Figure 3 and
Figure S1). While E163R trabeculae behaved like WT, R92Q
trabeculae exhibited a blunted response to changes in
stimulation frequency and to other inotropic interventions,
as previously shown in Langendorff-perfused working
hearts.39 Experiments in isolated cardiomyocytes confirmed
that E-C coupling abnormalities were mostly present in the
R92Q mouse model (Figure 4). As previously described,38
R92Q cardiomyocytes exhibited smaller and slower Ca2+
transients compared with WT, providing a reasonable expla-
nation for diastolic dysfunction in vivo. Differently, in E163R
cardiomyocytes, the kinetics of Ca2+ transients were normal
(Figure 4) and no major E-C coupling changes were found that
could explain prolonged twitch duration in trabeculae. Exper-
iments performed in single myofibrils and skinned ventricular
trabeculae showed that E163R uniquely alters the switched-
off state of the thin filament in the absence of Ca2+
(Figures 6, 7 and Figure S4), thus directly impairing the
mechanics and energetics of cardiac relaxation and diastole.
In addition, simultaneous measurements of isometric tension
and ATPase demonstrated that the energy cost of tension
generation was increased in E163R but unchanged in R92Q
trabeculae (Figure 7 and Figure S5), the latter in line with
previous observations.28 Despite these differences, some
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↑CaMKII acvity
↑ ↑ Diastolic Ca2+ levels
↓SERCA acvity
↑  Diastolic Ca2+ levels
↑ Ca2+ sensivity↑Tension Cost
Increased myofilament resng tension
Major role of 
Sarcomeric changes HCM 
phenotype
R92QE163R
Major role of 
EC coupling alteraons
RyR2
Na+channel
Ca2+ channel
NCX
SERCAPLB
↑ CaMKII acvity
LV hypertrophy, diastolic dysfuncon, arrhythmias
Figure 8. Different mutation-specific mechanisms lead to similar phenotypes. Scheme depicting the
proposed mutation-specific molecular and cellular mechanisms leading to hypertrophic cardiomyopathy
(HCM)–related cardiac structural and functional abnormalities in mice carrying the R92Q or E163
mutations. The figure includes 2 short-axis magnetic resonance scans (mid-left ventricular [LV] level) at end
diastole from mice of the 2 strains, obtained with a 7T magnetic resonance setup. CaMKII indictes calcium/
calmodulin-dependent protein kinase II; E-C, excitation-contraction.
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similarities were observed. Myofilament Ca2+ sensitivity in
skinned trabeculae was increased in both HCM mutant lines
compared with WT, although the change was much greater in
the R92Q model (Figure 7). Intramyocardial fibrosis was
increased in both mouse lines as compared with WT, but the
extent was much larger in R92Q hearts (Figure 4). In
cardiomyocytes, diastolic Ca2+ levels and CaMKII autophos-
phorylation were abnormally elevated in both mutant lines,
with greater changes occurring in the R92Q model (Figure 4).
Increased myofilament Ca2+ sensitivity and cytosolic Ca2+
overload may be plausibly linked to the increased rate of
arrhythmias observed with both mutations. Overall, these
results indicate that similar HCM phenotypes can be gener-
ated through different pathogenic pathways (see scheme in
Figure 8). In the E163R model, mutation-driven abnormalities
in myofilament function largely account for cardiac dysfunc-
tion. In the R92Q model, instead, profound E-C coupling
changes related to aggressive cardiomyocyte remodeling
seem to drive the cardiac HCM phenotype (Figure 8).
In addition to the comprehensive biophysical character-
ization in 6-month-old mice, data obtained at different ages,
including 3 months and 12 months, are reported in Fig-
ure S6. Studies of 3-month-old mutant mice demonstrated
that both sarcomere and E-C coupling changes are already
present, although in R92Q mice, some of the intracellular
calcium alterations (eg, increased diastolic Ca2+ levels,
prolonged Ca2+ transient duration) are more severe in older
animals, while no progression was observed in the E163R
model.
Primary Sarcomeric Changes Directly Impair
Energetics and Diastolic Function in E163R
Hearts
While all mechanical and kinetic parameters of maximally
activated R92Q myofibrils were the same as those of WT
myofibrils, in E163R myofibrils, kinetics of force generation
(tension activation and tension redevelopment) and isometric
relaxation (slow kREL) were significantly faster compared with
both WT and R92Q, preparations suggesting that the mutation
primarily affects crossbridge kinetics and energetics. Accord-
ing to a simple crossbridge model, these results indicate that
a modest (but significant) increase in gapp (the apparent rate
with which crossbridges leave their force-generating state
under isometric conditions) in E163R mice accounts for both
faster crossbridge turnover and increased tension cost,
without significantly affecting maximal tension generation.9
As to the impact of E163R on gapp, pioneer studies reviewed
by Gordon et al40 reported that HCM-associated cardiac TnT
mutations may cause changes in regulated acto-S1 ATPase
and unloaded thin filament sliding speed. This implies that
cardiac TnT can modulate strongly bound crossbridge
detachment rate in addition to its ability to control the
attachment of crossbridges to the thin filament. However, the
potential molecular mechanism of this effect of the E163R
mutation remains unclear.
In spite of the faster rate of the slow isometric phase of
relaxation following Ca2+ removal, overall relaxation from
maximal activation was prolonged in E163R myofibrils
(slower fast kREL and prolonged duration of the early
isometric phase), while resting tension was significantly
higher compared with WT and R92Q myofibrils (Figure 6).
This behavior, together with the increase in resting tension,
suggests that in E163R sarcomeres, the thin filament may
not turn off properly upon Ca2+ removal and may be unable
to fully maintain its switched-off state during diastole, in
analogy with previously described HCM-related tropomyosin
mutations.41–43 The modest increase in myofilament Ca2+
sensitivity in E163R myocardium is in line with previous
findings44 and may be a consequence of the impaired thin
filament blocked state that allows recruitment of some
force-generating crossbridges at low Ca2+.24,45,46 We
excluded that the increase of myofilament Ca2+ sensitivity
depended on a reduction of troponin I phosphorylation at the
protein kinase A site (Figure S3), although we have not
explored other possible posttranslational modifications of
sarcomere proteins (eg, MyPBC3). The observed increase of
resting ATPase in E163R skinned trabeculae and myofibrils
is likely a direct consequence of residual thin filament
activation at low [Ca2+]. Residual thin filament activation
following Ca2+ removal may promote formation of new
crossbridges,41–43 contributing to slow down relaxation, and
increase diastolic tension in E163R myocardium. These
sarcomeric abnormalities are likely to be the basis of the
prolonged twitch contraction and the impaired diastolic
function observed in vivo (Figure 8).
While these considerations suggest that altered sarcomere
function is the main pathogenic element underlying impaired
relaxation in E163R myocardium, a contribution of other
mechanisms cannot be excluded. For instance, previous
work24 described considerable degrees of myofibril disarray
and Z-line misalignment in E163R cardiomyocytes. This is
consistent with the modest structural disorganization of T-
tubules observed in E163R myocytes and may contribute to
impair cardiomyocyte relaxation properties.26
Moreover, the expression of mutant TnT protein in the
R92Q line is 67%,13,23 while it is 50% in the E163R line.24
Such a difference is unlikely to have accounted for the
observed divergences in myofilament energetics and myofibril
relaxation between the 2 lines; however, we cannot exclude
that the higher expression of mutant protein in R92Q mice
affects some features of myocardial dysfunction in mutant
mice (eg, myofilament Ca2+ sensitivity) and acknowledge this
issue as a limitation of our work.
DOI: 10.1161/JAHA.116.005407 Journal of the American Heart Association 15
Mutation-Specific Pathomechanisms in Hypertrophic Cardiomyopathy Ferrantini et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on D
ecem
ber 3, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
Secondary E-C Coupling Changes are the Major
Cause for Contractile Dysfunction in R92Q
Diastolic dysfunction evaluated in vivo through echocardiog-
raphy was more severe in R92Q compared with E163R mice.
Mechanical measurements in intact trabeculae confirmed that
twitch contraction was prolonged. In addition, despite
preserved baseline systolic contraction, inotropic reserve
was reduced in R92Q, at variance with E163R preparations
(Figure 2 and 3). Reduced contractile reserve is a feature of
adverse remodeling and disease progression in human HCM,
previously observed in transgenic mice carrying different TnT
mutations in the same locus.47 Approximately 20% of HCM
patients showed an insufficient blood pressure response to
exercise and 10% displayed overt systolic dysfunction (ejec-
tion fraction <50%).3 Both features are validated predictors of
adverse outcome and sudden cardiac death in patients with
HCM.48
At variance with E163R cells, R92Q cardiomyocytes
display severe prolongation of Ca2+ transient decay, which
can account for prolonged twitch duration and contribute to
the diastolic dysfunction observed in vivo (Figure 8). A
number of mechanisms may contribute to this aspect. First,
we confirmed47 that the reduced SERCA activity underlies the
slower kinetics of Ca2+ transients in R92Q cells and is caused
by a lower SERCA expression paralleled by increased
phospholamban expression and phosphorylation levels (Fig-
ure S3). The reduction of SR Ca2+ recirculation fraction
observed in R92Q trabeculae further confirms the reduction of
SERCA activity.26 Interestingly, cardiomyocytes isolated from
septal samples of patients with obstructive HCM undergoing
myectomy consistently displayed slower Ca2+ transients,
associated with reduced SERCA expression.22 Furthermore,
slower Ca2+ transient kinetics and reduction in SERCA
expression have been observed in the majority of animal
models with experimental LVH and LV failure and in
cardiomyocytes from patients with terminal heart failure.49
Thus, it does not represent a disease-specific feature.
Similarly, as in human HCM,50 we describe a certain degree
of T-tubule disruption in R92Q cardiomyocytes, in line with our
previous data on D160 cardiac TnT mutant mouse model.18
The extent of T-tubule structural remodeling in R92Q
cardiomyocytes, however, is much less pronounced compared
with models of secondary hypertrophy and failure51 and is
likely to play only a minor role in the slowing of Ca2+ transient
and contraction kinetics. In parallel with a large number of
HCM mutations in thin and thick filament proteins, we
observed a large increase in myofilament Ca2+ sensitivity in
R92Q skinned trabeculae, likely related to higher Ca2+ binding
affinity of troponin complexes incorporating the mutant
protein.46 As a consequence, myofilament Ca2+ dissociation
is slower and may contribute to prolong the last phase of Ca2+
transient decay, resulting in increased end-diastolic [Ca2+].35
Increased myofilament Ca2+ sensitivity in combination with
reduced SERCA activity can explain the elevated diastolic
[Ca2+]i and excessive increase in baseline [Ca
2+]i at high
stimulation frequencies, which were particularly prominent in
R92Q myocytes. In E163R myocardium, we found a slight
reduction of SERCA expression and a minimal increase of
phospholamban expression and phosphorylation compared
with WT myocardium (Figure S3). Such changes were much
less pronounced with respect to R92Q hearts and are unlikely
to determine a significant slowing of SERCA Ca2+-reuptake
rate, as indicated by the preserved Ca2+ transient decay rate
in E163R myocytes. Therefore, increased myofilament Ca2+
sensitivity could be the sole cause of the increase of diastolic
[Ca2+]i observed in E163R myocardium.
35
As previously shown in human HCM myocardium,22 a
sustained increase in diastolic [Ca2+]i is associated with
enhanced activation of CaMKII, as confirmed by the higher
degree of CaMKII autophosphorylation observed in R92Q
myocardium. Increased CaMKII activity plays a central role in
driving cellular and extracellular remodeling in a number of
genetic and acquired cardiac diseases,52 including HCM,22
and may play a leading role in R92Q mice. In line with the
lesser degree of cellular remodeling and the less prominent
increase of diastolic [Ca2+]i in E163R versus R92Q myocytes
(Figure 4), the increase of CaMKII autophosphorylation was
less pronounced in E163R myocardium as compared with
R92Q. CaMKII activates transcription factors that drive
increased myocardial fibrosis in cardiac diseases.53 In line
with that, fibrosis was more pronounced in hearts from R92Q
mice compared with E163R mice. Of note, both mouse lines
well reproduce the increased CaMKII activity, recently
observed in myectomy samples from HCM patients22,37 and
described in humans as a hallmark of myofilament-positive
HCM.
Other pathways of hypertrophic remodeling, including the
nuclear factor of activated T cell pathway, do not appear to be
changed in either of the 2 mutant lines (Figure S3), consistent
with studies on human samples.37
Cellular Mechanisms of Arrhythmias in R92Q and
E163R Myocardium: Open Questions
Increased arrhythmogenesis in hearts from patient and animal
models with HCM is the result of pathological changes that
occur both at the cell and tissue level. The latter include
intramyocardial fibrosis, myocyte disarray, and regional
hypertrophy, which all promote the establishment of reentrant
arrhythmias. In the present work, we found that the mech-
anism underlying the increased rate of premature beats
during prolonged pauses and b-adrenergic stimulation in
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trabeculae was likely an increased rate of spontaneous Ca2+
waves and Ca2+ transients in cardiomyocytes, providing a
trigger for propagated contractions. In recent work on a
mouse model of catecholaminergic polymorphic ventricular
tachycardia,27 we showed that Ca2+-dependent cellular
arrhythmias depend on the increased open probability of
the ryanodine receptor (RyR), and that increased RyR open
probability alone causes faster mechanical restitution. Indeed,
in both R92Q and E163R mutants, and previously in the D160
TnT mouse line,18 we observed a faster rate of mechanical
restitution. This suggests that in TnT mutants, Ca2+ waves are
mediated by an increased RyR open probability during
diastole. The increase in diastolic cytosolic [Ca2+]i, observed
in cells from both TnT mouse lines, is the most direct
explanation for the observed instability of RyR channels, as
the main trigger for RyR opening is [Ca2+] at the dyad level.
However, in our experimental conditions, maximal diastolic
[Ca2+]i is observed at high pacing rates, while Ca
2+ waves are
more frequent during prolonged pauses. An alternative
explanation has been provided by Knollman et al,35 who
found that in HCM-linked TnT mutations, high myofilament
Ca2+ sensitivity leads to increased cytosolic Ca2+-buffering
capacity. The excessive amount of Ca2+ that binds to the
myofilaments is slowly released during pauses and accumu-
lates in the SR, determining SR Ca2+ overload, thus enhancing
RyR open probability through luminal control.54 This may
represent the main trigger for Ca2+ waves and delayed
afterdepolarizations during pauses. The proposed mechanism
occurs only in the presence of a mutation that increases the
binding rate of Ca2+ to the troponin complex. This is likely the
case for R92Q mutation. Whether the E163R mutation affects
Ca2+ binding to myofilaments and intracellular Ca2+ buffering
remains to be determined.
Implications for Human Disease
Our data support the view that different mutations, even within
the same gene, can generate cardiac dysfunction with
markedly different mechanisms. While diastolic dysfunction
and arrhythmogenesis are common consequences of all HCM
mutations, a complex structural and functional remodeling of
cardiomyocytes may occur only with certain variants, such as
R92Q, and may not be present in others, such as E163R.
Interestingly, mutations at the R92 site of TNNT2 are regarded
as severe, with a high risk of lethal arrhythmias during
adolescence and early adulthood,55,56 while mutations at the
E163 site lead to milder forms of HCM.57 The notion that
cellular remodeling is mutation specific may be relevant for
treatment. Drugs targeting membrane ion channels, such as
late Na-current blockers22 or diltiazem,58 may be more
effective in the presence of significant cardiomyocyte E-C
coupling remodeling. We previously showed that in R92Q
cardiomyocytes, the late Na+-current blocker ranolazine
(10 lmol/L) significantly hastened Ca2+ transient kinetics
and reduced diastolic Ca2+ and the rate of spontaneous beats
and Ca2+ waves.30 Additionally, lifelong treatment with
ranolazine preventedmost of the aspects of cardiac remodeling
and dysfunction in R92Qmice.30 Contrarily, recent unpublished
experiments show that the acute administration of ranolazine is
unable to exert similar effects on E163R cardiomyocytes.
The same can be said for drugs that act on extracellular
remodeling, such as sartans or statins, which have shown
promising results in transgenic HCM animal models with
selected “severe” mutations59,60 but failed to show convinc-
ing results in patients who were not selected based on
genotype.61,62 Conversely, in the presence of sarcomeric
mutations leading to cardiac dysfunction through direct
mechanisms, sarcomere-targeting drugs may be preferred,
such as novel myosin inhibitors, currently in the pipeline for
the treatment of HCM.63
Conclusions
Based on the results of the present investigation, we envision
a future where the treatment of every patient will be decided
based on his/her specific mutation, driven by studies of the
specific mutation-linked mechanisms of disease. Although we
understand that producing animal models as a predictive tool
is not practical, cardiomyocytes differentiated from patient-
specific induced pluripotent stem cells may be a feasible tool
to assess mutation-specific pathomechanisms and predict the
efficacy of drugs in individual patients.19,64
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